TrialObesity (Silver Spring, Md.)2026

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.

Harold E Bays et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.